Qilu is lined up to copy 1 of the blockbuster drugs on this tracker, which earned $31.7B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Qilu's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Keytruda | Merck | Biosimilar | 2028 | US partnership signed, Sep 2026 | $31.7B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Qilu's share of it.